Financial Trade Freedom - Investing and Stock News
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
No Result
View All Result
Financial Trade Freedom - Investing and Stock News
No Result
View All Result
Home Stock

Europe bulletin: UK budget pressure, Novo’s Alzheimer’s blow, new Ukraine-US peace push

admin by admin
November 24, 2025
in Stock
0
Europe bulletin: UK budget pressure, Novo’s Alzheimer’s blow, new Ukraine-US peace push
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Europe is grappling with a mix of political pressure, corporate setbacks, and geopolitical maneuvering.

UK business leaders are calling for a sharper, growth-focused budget, while Novo Nordisk faces disappointment after its Alzheimer’s drug failed a key trial.

In France, a telecom union is challenging Amazon’s satellite ambitions over security concerns, and on the global stage, the US and Ukraine are quietly reshaping a peace plan aimed at ending Russia’s war, highlighting the region’s urgent and shifting priorities.

A glance at the major developments in Europe today.

UK businesses push for bold budget

UK business leaders, including the head of the Confederation of British Industry, are urging Finance Minister Rachel Reeves to make some tough, focused choices in her upcoming budget.

They warned that spreading lots of small tax hikes across the economy could actually do more harm than good.

Their main message? The government needs to zero in on policies that genuinely support growth.

That means tackling high energy costs, updating labour rules, and working more closely with businesses to get reforms right.

They said they back the government’s broader plans for industry and infrastructure, but they’re worried about rising pension-related costs making it harder for companies to hire.

At the same time, the government is looking into ways to bring down energy bills for manufacturers from 2027, hoping it will help keep UK industries competitive.

Novo Alzheimer’s trial falls short

Shares of Novo Nordisk slipped after the company announced that its oral semaglutide, the same drug behind its popular weight-loss treatments, didn’t show any real clinical benefit in Phase 3 trials for early-stage Alzheimer’s.

The two big studies, evoke and evoke+, followed more than 3,800 people over two years.

And while the drug did improve some biomarkers linked to the disease, it ultimately didn’t slow cognitive decline any better than a placebo.

Novo Nordisk said it pursued the trials because there’s such a huge unmet need in Alzheimer’s research, even though they knew the chances of success were low.

With the disappointing outcome, the company is shutting down the extension phase of the trials and plans to share full results at an upcoming medical conference.

It’s definitely a setback for hopes that a weight-loss drug could also make a difference in Alzheimer’s.

French union challenges Amazon Kuiper license

A French telecom union is pushing back against Arcep’s decision to let Amazon use French radio frequencies for its satellite internet project, known as Project Kuiper.

The union has taken the case all the way to France’s highest administrative court, arguing that the regulator didn’t do a proper market review and skipped a competitive bidding process altogether.

They say the move raises big questions about public safety, data privacy, and national security, especially since the operator isn’t European.

The challenge comes at a time when France is already keeping a close eye on major US tech companies, and competition in satellite internet is heating up with players like Elon Musk’s Starlink.

Amazon, meanwhile, is moving ahead with plans to launch a huge network of satellites between 2025 and 2026.

US, Ukraine rework peace proposal

The US and Ukraine are working together to rewrite a US-backed peace plan aimed at ending Russia’s invasion, after concerns that the original proposal leaned too much in Moscow’s favor.

Following talks in Geneva, the two sides said they’ve come up with a “refined peace framework” that better reflects Ukraine’s priorities, though they’re keeping the specifics under wraps for now.

A big part of the challenge is figuring out how to handle the toughest issues, things like contested territory, military restrictions, and Ukraine’s future with NATO.

Critics have argued that the earlier plan pushed Ukraine toward making too many concessions, while European allies have been trying to soften some of those points.

Negotiations are still intense, and leaders are scrambling to find a realistic way to end what has become Europe’s deadliest war since World War II.

The post Europe bulletin: UK budget pressure, Novo’s Alzheimer’s blow, new Ukraine-US peace push appeared first on Invezz


Previous Post

US midday market brief: how Fed-cut odds, AI bets & crypto moves are driving today’s tape

Next Post

Why retail sales data this week is of particular importance for markets

Next Post
Why retail sales data this week is of particular importance for markets

Why retail sales data this week is of particular importance for markets

  • Trending
  • Comments
  • Latest
U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

February 19, 2025
How Companies Use Derivatives To Hedge Risk

How Companies Use Derivatives To Hedge Risk

February 19, 2025
KFC moves U.S. headquarters from Kentucky to Texas

KFC moves U.S. headquarters from Kentucky to Texas

February 19, 2025
Cross-Currency Swap: Definition, How It Works, Uses, and Example

Cross-Currency Swap: Definition, How It Works, Uses, and Example

February 19, 2025
Why Tesla stock is soaring over 6% today

Why Tesla stock is soaring over 6% today

0
From tariffs to DOGE, what companies are saying about the impact of MAGA policies

From tariffs to DOGE, what companies are saying about the impact of MAGA policies

0
Tesla’s law firm drafts Delaware bill that could salvage Musk pay package

Tesla’s law firm drafts Delaware bill that could salvage Musk pay package

0
Coca-Cola takes on Olipop and Poppi with new prebiotic soda brand, Simply Pop

Coca-Cola takes on Olipop and Poppi with new prebiotic soda brand, Simply Pop

0
Why Tesla stock is soaring over 6% today

Why Tesla stock is soaring over 6% today

November 24, 2025
Nvidia stock edges higher as investors await US decision on China chip exports

Nvidia stock edges higher as investors await US decision on China chip exports

November 24, 2025
Oscar Health stock: why Obamacare extension isn’t a strong enough reason to own it

Oscar Health stock: why Obamacare extension isn’t a strong enough reason to own it

November 24, 2025
US bank profits climb in Q3 as loss provisions ease, FDIC says

US bank profits climb in Q3 as loss provisions ease, FDIC says

November 24, 2025

    Get Smarter with Your Money – Sign Up for Free Financial Tips!


    Join our community of savvy savers and investors! By signing up, you'll receive weekly emails packed with personalized financial tips, budgeting hacks, and investment strategies tailored to your income level. Take control of your finances today – it’s free and only takes a minute!

    Recent News

    Why Tesla stock is soaring over 6% today

    Why Tesla stock is soaring over 6% today

    November 24, 2025
    Nvidia stock edges higher as investors await US decision on China chip exports

    Nvidia stock edges higher as investors await US decision on China chip exports

    November 24, 2025
    Oscar Health stock: why Obamacare extension isn’t a strong enough reason to own it

    Oscar Health stock: why Obamacare extension isn’t a strong enough reason to own it

    November 24, 2025
    US bank profits climb in Q3 as loss provisions ease, FDIC says

    US bank profits climb in Q3 as loss provisions ease, FDIC says

    November 24, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved

    No Result
    View All Result
    • About us
    • Contacts
    • Email Whitelisting
    • Investing and Stock News
    • Privacy Policy
    • Terms and Conditions
    • Thank you

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved